Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $14.50 for the day, up 2.91% from the previous closing price of $14.09. In other words, the price has increased by $2.91 from its previous closing price. On the day, 0.55 million shares were traded. ZYME stock price reached its highest trading level at $14.77 during the session, while it also had its lowest trading level at $14.11.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.10. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on November 07, 2024, Upgraded its rating to Outperform and sets its target price to $25 from $10 previously.
On November 01, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 ’24 when Galbraith Kenneth sold 18,198 shares for $10.65 per share. The transaction valued at 193,849 led to the insider holds 29,468 shares of the business.
Galbraith Kenneth sold 5,706 shares of ZYME for $63,996 on Jan 08 ’24. The Chair & CEO now owns 23,762 shares after completing the transaction at $11.22 per share. On Jan 05 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 4,563 shares for $10.65 each. As a result, the insider received 48,606 and left with 7,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 998723840 and an Enterprise Value of 721802112. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.82 while its Price-to-Book (P/B) ratio in mrq is 2.77. Its current Enterprise Value per Revenue stands at 11.605 whereas that against EBITDA is -6.293.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is 4.32%, while the 200-Day Moving Average is calculated to be 31.36%.
Shares Statistics:
ZYME traded an average of 572.81K shares per day over the past three months and 427970 shares per day over the past ten days. A total of 69.58M shares are outstanding, with a floating share count of 67.09M. Insiders hold about 3.39% of the company’s shares, while institutions hold 97.30% stake in the company. Shares short for ZYME as of 1731628800 were 4208640 with a Short Ratio of 7.35, compared to 1728950400 on 4163667. Therefore, it implies a Short% of Shares Outstanding of 4208640 and a Short% of Float of 7.53.
